Short-term efficacy and safety of camrelizumab-based treatment in refractory or metastatic esophageal squamous cell carcinoma
Our study has shown that camrelizumab in combination with apatinib is a promising therapy for patients with refractory or metastatic ESCC. This combination has a high response rate and favorable clinical safety.
Authors
- Qingliang Meng
- Xiaowu Li
- Youwei Zhang (ORCID: https://orcid.org/0000-0001-9374-329X)
- Sanyuan Sun (ORCID: https://orcid.org/0000-0002-7477-7491)
- Yuan Yuan (ORCID: https://orcid.org/0009-0002-9540-2100)
Institutions
- Xuzhou Central Hospital (CN)
Publication Details
- Journal
- Indian Journal of Cancer
- Published
- 2024-10-01
- DOI
- https://doi.org/10.4103/ijc.ijc_1275_20
- Citations
- 1
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.57